Posted May. 3, 2012 at 9:13 a.m.

Premium Lock Charlotte firm may seek narrower use for drug to treat Parkinson's sympton

Published: 2012-05-03 09:13:23
Updated: 2012-05-03 09:13:23

FDA FDA

If results of an ongoing phase 3 study don't support the durability of Northera's effect over time, Chelsea Therapeutics "might seek to obtain approval for Northera as an acute rather than a chronic treatment."...

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2014 MedCity. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Scroll